ILr1β production is dependent on the activation of purinergic receptors and NLRP3 pathway in human macrophages
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
The Nod‐like receptor family protein 3 (NLRP3)‐inflammasome pathway is known to be activated by danger signals such as monosodium urate (MSU). We investigated the role of P2 purinergic receptors in the activation of NLRP3‐inflammasome pathway after MSU treatment of primary human monocyte‐derived macrophages (MDMs). After initial stimulation with a low concentration of LPS (0.1 μg/ml), a 6 h treatment with MSU crystals (250, 500, and 1000 μg/ml) induced the MDMs to release IL‐1β, IL‐1α, and IL‐6 in a dose‐dependent manner. Moreover, the caspase 1 inhibitor Z‐YVAD‐FMK and the cathepsin B inhibitor CA‐074Me reduced production of IL‐1β in a dose‐dependent manner after LPS + MSU treatment We used real‐time reverse transcription‐quantitative PCR to show that treatment with LPS and MSU (500 μg/ml) induced significantly greater expression of NLRP3 and IL‐1β than after treatment with LPS. We also found that MSU treatment induced P2X purinergic receptor 7 (P2X7R) mRNA and protein expression. Furthermore, addition of the P2X7 purinergic receptor antagonist A‐740003 significantly impeded IL‐1β production and pro‐IL‐1β cleavage after treatment with LPS + MSU. Remarkably, RNA silencing of P2X7R (but not P2X4R) inhibited the release of IL‐1β and other M1 macrophage cytokines (such as IL‐1α, IL‐6, and TNF‐α) from MDMs stimulated with LPS + MSU. Taken as a whole, our results show that P2 purinergic receptors and the NLRP3 inflammasome pathway are involved in the secretion of IL‐1β from MSU‐stimulated human macrophages. This pathway may constitute a novel therapeutic target for controlling the inflammatory process in several associated pathologies.—Gicquel, T., Robert, S., Loyer, P., Victoni, T., Bodin, A., Ribault, C., Gleonnec, F., Couillin, I., Boichot, E., Lagente, V. IL‐1β production is dependent on the activation of purinergic receptors and NLRP3 pathway in human macrophages. FASEB J. 29, 4162‐4173 (2015). www.fasebj.org
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Martinon, F., Burns, K., & Tschopp, J. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00599-3 · Cited by 6,066
Gout-associated uric acid crystals activate the NALP3 inflammasome
Martinon, F., Pétrilli, V., Mayor, A., Tardivel, A., & Tschopp, J. (2006) · Nature · doi:10.1038/nature04516 · Cited by 5,326
The M1 and M2 paradigm of macrophage activation: Time for reassessment
Martinez, F. O., & Gordon, S. (2014) · F1000Prime Reports · doi:10.12703/p6-13 · Cited by 4,689 · cited 1×
“M1 stimuli (such as LPS and GM-CSF) induce a prototypic inflammatory response, whereas M2 stimuli antagonize this response (51).”
BackgroundNLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
Duewell, P., Kono, H., Rayner, K. J., Sirois, C. M., Vladimer, G., Bauernfeind, F. G., Abela, G. S., Franchi, L., Nuñez, G., Schnurr, M., et al. (2010) · Nature · doi:10.1038/nature08938 · Cited by 4,026
Cryopyrin activates the inflammasome in response to toxins and ATP
Mariathasan, S., Weiss, D. S., Newton, K., McBride, J., O'Rourke, K., Roose-Girma, M., Lee, W. P., Weinrauch, Y., Monack, D. M., & Dixit, V. M. (2006) · Nature · doi:10.1038/nature04515 · Cited by 3,080 · cited 1×
“Extracellular ATP is the best-known danger signal in NLRP3 activation [via stimulation of the P2X7 purinergic receptor (P2X7R) (9, 10), potassium efflux (11), and recruitment of pannexin-1 channel (12)].”
BackgroundHornung, V., Bauernfeind, F., Halle, A., Samstad, E. O., Kono, H., Rock, K. L., Fitzgerald, K. A., & Latz, E. (2008) · Nature Immunology · doi:10.1038/ni.1631 · Cited by 3,065 · cited 14×
“The NLRP3-inflammasome pathway is known to be involved inmany inflammatory diseases.”
BackgroundInfluentialInnate Immune Activation Through Nalp3 Inflammasome Sensing of Asbestos and Silica
Dostert, C., Pétrilli, V., Van Bruggen, R., Steele, C., Mossman, B. T., & Tschopp, J. (2008) · Science · doi:10.1126/science.1156995 · Cited by 2,658
The NALP3 inflammasome is involved in the innate immune response to amyloid-β
Halle, A., Hornung, V., Petzold, G. C., Stewart, C. R., Monks, B. G., Reinheckel, T., Fitzgerald, K. A., Latz, E., Moore, K. J., & Golenbock, D. T. (2008) · Nature Immunology · doi:10.1038/ni.1636 · Cited by 2,441
Agostini, L., Martinon, F., Burns, K., McDermott, M. F., Hawkins, P. N., & Tschopp, J. (2004) · Immunity · doi:10.1016/s1074-7613(04)00046-9 · Cited by 1,768 · cited 1×
“Activationof theNLRP3-inflammasome pathway appears to be the cornerstone of many inflammatory diseases, including Crohn disease (2), rheumatoid arthritis (3), cryopyrin-associated periodic syndrome (4), idiopathic pulmonary fibrosis (5, 6), and gout (7).”
BackgroundMolecular identification of a danger signal that alerts the immune system to dying cells
Shi, Y., Evans, J. E., & Rock, K. L. (2003) · Nature · doi:10.1038/nature01991 · Cited by 1,684
Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration
Pétrilli, V, Papin, S., Dostert, C., Mayor, A., Martinon, F., & Tschopp, J. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402195 · Cited by 1,445 · cited 1×
“Extracellular ATP is the best-known danger signal in NLRP3 activation [via stimulation of the P2X7 purinergic receptor (P2X7R) (9, 10), potassium efflux (11), and recruitment of pannexin-1 channel (12)].”
BackgroundLiu‐Bryan, R., Scott, P., Sydlaske, A., Rose, D. M., & Terkeltaub, R. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21238 · Cited by 414
Uric Acid Is a Danger Signal Activating NALP3 Inflammasome in Lung Injury Inflammation and Fibrosis
Gasse, P., Riteau, N., Charron, S., Girre, S., Fick, L., Pétrilli, V., Tschopp, J., Lagente, V., Quesniaux, V. F. J., Ryffel, B., et al. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200808-1274oc · Cited by 410
Self-citationExtracellular ATP Is a Danger Signal Activating P2X7 Receptor in Lung Inflammation and Fibrosis
Riteau, N., Gasse, P., Fauconnier, L., Gombault, A., Couegnat, M., Fick, L., Kanellopoulos, J., Quesniaux, V. F. J., Marchand-Adam, S., Crestani, B., et al. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201003-0359oc · Cited by 397 · cited 3×
“According to data in the literature, MSU induces the production of various inflammatory cytokines (including IL-1b and IL-6) by THP-1 cells and mouse macrophages (5, 6).”
BackgroundSelf-citation
Cited by
Purinergic regulation of the immune system
Cekic, C., & Linden, J. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.4 · Cited by 787
Interplay Between NLRP3 Inflammasome and Autophagy
Biasizzo, M., & Kopitar-Jerala, N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.591803 · Cited by 605
The P2X7 receptor: A main player in inflammation
Adinolfi, E., Giuliani, A. L., De Marchi, E., Pegoraro, A., Orioli, E., & Di Virgilio, F. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.12.021 · Cited by 385
Robert, S., Gicquel, T., Victoni, T., Valença, S., Barreto, E., Bailly-Maître, B., Boichot, E., & Lagente, V. (2016) · Bioscience Reports · doi:10.1042/bsr20160107 · Cited by 190
Self-citationP2X7 Receptor Expression in Patients With Serositis Related to Systemic Lupus Erythematosus
Furini, F., Giuliani, A. L., Parlati, M. E., Govoni, M., Di Virgilio, F., & Bortoluzzi, A. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00435 · Cited by 37
Metadata
- Authors
- Gicquel, T., Robert, S., Loyer, P., Victoni, T., Bodin, A., Ribault, C., Gleonnec, F., Couillin, I., Boichot, E., & Lagente, V.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2015-06-26
- Volume
- 29
- Issue
- 10
- Pages
- 4162-4173
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2132430680
- Cited by
- 123
- References
- 15
- FWCI
- 5.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.